Figure 1.

Histographical display of crude all-cause mortality (percent) over a mean 7.7-year follow-up in 11,322 CAD patients – nondiabetic and diabetic – on several therapeutic regimens. Mortality in patients on a combined glibenclamide/metformin regimen was significantly higher and almost quadrupled the figures documented for nondiabetic CAD patients. Significant statistical differences were still present when comparing the group on combined pharmacotherapy with the groups on other antidiabetic regimes. ND – nondiabetics; diet – patients solely on diet; gliben – patients on glibenclamide; metfor – patients on metformin; comb – patients on a combined glibenclamide/metformin regimen. (Based on data from Ref. [45]).